Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHEK2/RAD53 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHEK2 Recombinant Protein (Active Kinase) High purity (>90% by SDS-PAGE), Sequence Verified, Endotoxin Controlled. Suitable for high-throughput enzymatic screening. |
View CHEK2 Products |
| Gene Delivery | CHEK2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Crucial for cellular DNA damage response (DDR) reporter assays. |
View CHEK2 Products |
| Benchmark Ab | Anti-CHEK2 Recombinant Antibody Sequence-derived monoclonal antibody for Western Blot, Immunoprecipitation, and ELISA positive controls. |
View CHEK2 Products |
| Validator | CHEK2 siRNA Set Target-specific knockdown verification to eliminate off-target assay signals. |
View CHEK2 Products |
| Related Target A | ATM (Ataxia Telangiectasia Mutated) Upstream master kinase that phosphorylates and activates CHEK2 in response to double-strand breaks. |
View ATM Products |
| Related Target B | PARP1 (Poly [ADP-ribose] polymerase 1) Synergistic pathway target; combined inhibition of PARP and CHEK2 enhances synthetic lethality in HR-deficient tumors. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity Screening (avoiding CHEK1 off-target effects) | High-purity active recombinant CHEK2 and CHEK1 proteins available for parallel IC50 profiling. |
| Cell-based Pathway Validation | High-titer Lentiviral particles for stable target expression without transient transfection toxicity. |
| Lack of Reagent Standardization | Sequence-verified clinical benchmark antibodies included as reference controls. |
| False Positive Knockdown Signals | Validated siRNA pools included for orthogonal gene-silencing verification. |
Live CHEK2/RAD53 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHEK2 therapeutics is intensifying, with major players shifting focus from traditional non-selective kinase inhibitors to highly selective small molecules and PROTACs. As first-generation dual CHEK1/CHEK2 therapies reach clinical evaluation, the next wave of R&D is targeting selective CHEK2 inhibition to mitigate hematological toxicities associated with CHEK1 inhibition, especially in homologous recombination (HR)-deficient solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Pfizer, Eli Lilly, Sentinel Oncology | Breast Cancer, Prostate Cancer, Ovarian Cancer | Selectivity Assay (Need highly purified active CHEK2 WT vs Mutants) |
| PROTAC Degraders | Academic Institutes, Biotech Startups | DDR-Deficient Solid Tumors | Target Engagement & Degradation Assay (Need stable Lentivirus-expressed cell lines) |
| Combination Therapies | AstraZeneca, Merck | BRCA1/2 Mutated Malignancies | Synergy Validation (Need ATM/ATR pathway control reagents) |